Results 251 to 260 of about 19,226,899 (298)

Peginterferon Alfa-2a Alone, Lamivudine Alone, and the Two in Combination in Patients With HBeAg-Negative Chronic Hepatitis B

New England Journal of Medicine, 2004
BACKGROUND: Available treatments for hepatitis B e antigen (HBeAg)-negative chronic hepatitis B are associated with poor sustained responses. As a result, nucleoside and nucleotide analogues are typically continued indefinitely, a strategy ...
Patrick Marcellin, Ferruccio Bonino, Cihan Yurdaydın   +2 more
exaly   +1 more source

Some of the next articles are maybe not open access.

Related searches:

Hepatitis B virus replication modulates pathogenesis of hepatitis D virus in chronic hepatitis D

Hepatology, 1991
Hepatitis D virus and hepatitis B virus nucleic acids were detected by Northern and Southern blot hybridlzation in the sera and livers of 85 chronic carriers of HBsAg and anti-hepatitis D followed up for a mean of 10 yr. We identified three subsets of patients: 13 with hepatitis D virus and hepatitis B virus viremia, 53 with ...
SMEDILE, Antonina, ROSINA F., SARACCO, Giorgio Maria, CHIABERGE E., LATTORE V., FABIANO A., BRUNETTO MR, VERME G., RIZZETTO, Mario, BONINO F.   +9 more
openaire   +5 more sources

New Treatments for Chronic Hepatitis B Virus/Hepatitis D Virus Infection

Clinics in Liver Disease, 2021
Chronic hepatitis D virus (HDV) infection is the most severe form of viral hepatitis with high rates of end-stage liver disease and hepatocellular carcinoma. Therefore, effective antiviral treatment strategies are needed desperately. Until recently, antiviral treatment was limited to pegylated interferon-alpha.
Lisa, Sandmann, Heiner, Wedemeyer
openaire   +2 more sources

Chronic Hepatitis D; at a Standstill?

Digestive Diseases, 2016
Chronic hepatitis D (CHD) is a severe liver disease with worldwide distribution caused by the hepatitis D virus (HDV). Therapy of CHD is at a standstill. It still relies on interferon (IFN), introduced empirically in the 1980s; results are limited. With the peghilated IFNs that are now in use, only 25% of CHD reach a sustained viral response, that is ...
openaire   +2 more sources

Genotypes and Viremia of Hepatitis B and D Viruses Are Associated With Outcomes of Chronic Hepatitis D Patients

Gastroenterology, 2006
Genotypes and viremia of hepatitis D virus (HDV) and hepatitis B virus (HBV) may be associated with outcomes. This study evaluated the impact of viral genotypes and viremia on outcomes of dual HBV and HDV infection.Viremia and viral genotypes were analyzed in 194 consecutive chronic hepatitis B patients with HDV superinfection and correlated with ...
Chien-Wei, Su, Yi-Hsiang, Huang, Teh-Ia, Huo, Hsuan Hui, Shih, I-Jane, Sheen, Su-Wen, Chen, Pui-Ching, Lee, Shou-Dong, Lee, Jaw-Ching, Wu   +8 more
openaire   +2 more sources

Bulevirtide for Chronic Hepatitis D

New England Journal of Medicine, 2023
Hua, Fu, Yang, Liu, Qi, Liu
openaire   +2 more sources

Acute and Chronic Hepatitis B and D

1998
Viral hepatitis represents a diverse spectrum of clinical syndromes caused by a group of distinct viruses. All of the five well-characterized hepatitis viruses (A through E) are associated with acute hepatitis, whereas only hepatitis B virus (HBV), hepatitis C virus (HCV), and hepatitis D virus (HDV, delta agent) can cause chronic hepatitis (Table 1).
Steven A. Rogers, T. Jake Liang
openaire   +1 more source

Ribavirin treatment for chronic hepatitis D: a pilot study

Liver, 1994
To assess whether therapy with Ribavirin may affect the course of chronic delta hepatitis, nine Italian patients with this disease received the drug orally at a dosage of 15 mg/kg daily for 16 weeks. At the end of the therapy period, all patients were followed for 12 additional months. Seven patients completed the trial.
A. Garripoli, V. DI Marco, R. Cozzolongo, C. Costa, A. Smedile, A. Fabiano, F. Bonino, M. Rizzetto, G. Verme, A. Craxi, F. Rosina   +10 more
openaire   +3 more sources

The hepatitis delta virus and chronic hepatitis D

Journal of Hepatology, 2022
Maura Dandri, Annika Volmari, Marc Lütgehetmann   +2 more
openaire   +2 more sources

Treatment of Chronic Hepatitis D with Interferon Alfa-2a

New England Journal of Medicine, 1994
Chronic hepatitis D is a severe and rapidly progressive liver disease for which no therapy has been proved effective. To evaluate the efficacy of treatment with interferon, we studied 42 patients with chronic hepatitis D who were randomly assigned to receive either 9 million or 3 million units of recombinant interferon alfa-2a (three times a week for ...
Patrizia Farci, Antonella Mandas, Alessandra Coiana, Maria Eliana Lai, Valeer Desmet, Peter Van Eyken, Yukio Gibo, Luciano Caruso, Sergio Scaccabarozzi, Domenico Criscuolo, Jean-Charles Ryff, Angelo Balestrieri   +11 more
openaire   +2 more sources